Liposomal daunorubicin plasmatic and renal disposition in patients with acute leukemia View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2000-10

AUTHORS

Federico Pea, Domenico Russo, Mariagrazia Michieli, Massimo Baraldo, Anna Ermacora, Daniela Damiani, Michele Baccarani, Mario Furlanut

ABSTRACT

Liposomal formulations of anthracyclines have been developed to increase their delivery to solid tumors while reducing toxicity in normal tissues. DaunoXome (DNX, NeXstar) is a liposomal-encapsulated preparation of daunorubicin registered for treatment of Kaposi's sarcoma that during prior in vitro studies showed a toxicity to leukemic cells at least comparable to that of free daunorubicin. The aim of our study was to determine DNX pharmacokinetics in 11 poor-risk patients with acute leukemia treated with DNX 60 mg/m2 IV on days 1, 3, and 5. Blood and urine samples were collected at appropriate intervals after each of the three DNX administrations. The total amount of daunorubicin (free and entrapped) (t-DNR) and of its metabolite daunorubicinol (DNRol) was assayed by HPLC. The main pharmacokinetic parameters (t1/2alpha 4.54 +/- 0.87 h; VdSS 2.88 +/- 0.93 l/m2; Cl 0.47 +/- 0.26 l/h/m2) showed that in patients with acute leukemia liposomal-entrapped daunorubicin pharmacokinetics greatly differed from that observed for the conventional formulation. In fact, DNX produced mean plasma AUC levels (t-DNR AUC0-infinity 456.27 +/- 182.64 microg/ml/h) about 100- to 200-fold greater than those reported for the free drug at comparable doses due to a very much lower total body clearance. Volume of distribution at steady state was 200-to 500-fold lower than for the free drug. Plasma AUC of DNRol (17.62 +/- 7.13 microg/ml x h) was similar to or even greater than that observed with free daunorubicin for comparable doses. Cumulative urinary excretion showed that about 6% and 12% of the total dose of DNX administered was excreted in urine as daunorubicin and daunorubicinol, respectively. No major toxicity was encountered. Therefore, pharmacokinetic characteristics suggest that DNX may be more convenient than free daunorubicin in the treatment of acute leukemia. In fact, liposomal formulation may allow a reduction of daunorubicin captation in normal tissues. thus minimizing toxicity at least for the parent drug, and guarantee an unimpeded access to leukemic cells in the bloodstream and bone marrow, thus theoretically improving efficacy. More... »

PAGES

279-286

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s002800000163

DOI

http://dx.doi.org/10.1007/s002800000163

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1022931706

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/11052625


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Acute Disease", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibiotics, Antineoplastic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Calibration", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Daunorubicin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Carriers", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kidney", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Leukemia", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Liposomes", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pilot Projects", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Spectrometry, Fluorescence", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "University of Udine", 
          "id": "https://www.grid.ac/institutes/grid.5390.f", 
          "name": [
            "Institute of Clinical Pharmacology and Toxicology, Chair of Pharmacology, DPMSC, University of Udine, P.le S.M. Misericordia, 3, 33100 Udine, Italy e-mail: federico.pea@med.uniud.it Tel.: +39-0432-559833; Fax: +39-0432-559833, IT"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pea", 
        "givenName": "Federico", 
        "id": "sg:person.0725711337.51", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0725711337.51"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ospedale Santa Maria della Misericordia di Udine", 
          "id": "https://www.grid.ac/institutes/grid.411492.b", 
          "name": [
            "Department of Medical and Morphologic Research and Division of Hematology, Udine University Hospital, P.le S.M. Misericordia, 3, 33100 Udine, Italy, IT"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Russo", 
        "givenName": "Domenico", 
        "id": "sg:person.01033477037.24", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01033477037.24"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centro di Riferimento Oncologico", 
          "id": "https://www.grid.ac/institutes/grid.418321.d", 
          "name": [
            "Division of Medical Oncology, CRO, Istituto Nationale Tumori, Aviano, Italy, IT"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Michieli", 
        "givenName": "Mariagrazia", 
        "id": "sg:person.0633657425.75", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0633657425.75"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Udine", 
          "id": "https://www.grid.ac/institutes/grid.5390.f", 
          "name": [
            "Institute of Clinical Pharmacology and Toxicology, Chair of Pharmacology, DPMSC, University of Udine, P.le S.M. Misericordia, 3, 33100 Udine, Italy e-mail: federico.pea@med.uniud.it Tel.: +39-0432-559833; Fax: +39-0432-559833, IT"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Baraldo", 
        "givenName": "Massimo", 
        "id": "sg:person.0734230340.16", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0734230340.16"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ospedale Santa Maria della Misericordia di Udine", 
          "id": "https://www.grid.ac/institutes/grid.411492.b", 
          "name": [
            "Department of Medical and Morphologic Research and Division of Hematology, Udine University Hospital, P.le S.M. Misericordia, 3, 33100 Udine, Italy, IT"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ermacora", 
        "givenName": "Anna", 
        "id": "sg:person.01310754205.76", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01310754205.76"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ospedale Santa Maria della Misericordia di Udine", 
          "id": "https://www.grid.ac/institutes/grid.411492.b", 
          "name": [
            "Department of Medical and Morphologic Research and Division of Hematology, Udine University Hospital, P.le S.M. Misericordia, 3, 33100 Udine, Italy, IT"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Damiani", 
        "givenName": "Daniela", 
        "id": "sg:person.01104271471.84", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01104271471.84"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ospedale Santa Maria della Misericordia di Udine", 
          "id": "https://www.grid.ac/institutes/grid.411492.b", 
          "name": [
            "Department of Medical and Morphologic Research and Division of Hematology, Udine University Hospital, P.le S.M. Misericordia, 3, 33100 Udine, Italy, IT"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Baccarani", 
        "givenName": "Michele", 
        "id": "sg:person.01016466503.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01016466503.33"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Udine", 
          "id": "https://www.grid.ac/institutes/grid.5390.f", 
          "name": [
            "Institute of Clinical Pharmacology and Toxicology, Chair of Pharmacology, DPMSC, University of Udine, P.le S.M. Misericordia, 3, 33100 Udine, Italy e-mail: federico.pea@med.uniud.it Tel.: +39-0432-559833; Fax: +39-0432-559833, IT"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Furlanut", 
        "givenName": "Mario", 
        "id": "sg:person.01156366337.91", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01156366337.91"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2000-10", 
    "datePublishedReg": "2000-10-01", 
    "description": "Liposomal formulations of anthracyclines have been developed to increase their delivery to solid tumors while reducing toxicity in normal tissues. DaunoXome (DNX, NeXstar) is a liposomal-encapsulated preparation of daunorubicin registered for treatment of Kaposi's sarcoma that during prior in vitro studies showed a toxicity to leukemic cells at least comparable to that of free daunorubicin. The aim of our study was to determine DNX pharmacokinetics in 11 poor-risk patients with acute leukemia treated with DNX 60 mg/m2 IV on days 1, 3, and 5. Blood and urine samples were collected at appropriate intervals after each of the three DNX administrations. The total amount of daunorubicin (free and entrapped) (t-DNR) and of its metabolite daunorubicinol (DNRol) was assayed by HPLC. The main pharmacokinetic parameters (t1/2alpha 4.54 +/- 0.87 h; VdSS 2.88 +/- 0.93 l/m2; Cl 0.47 +/- 0.26 l/h/m2) showed that in patients with acute leukemia liposomal-entrapped daunorubicin pharmacokinetics greatly differed from that observed for the conventional formulation. In fact, DNX produced mean plasma AUC levels (t-DNR AUC0-infinity 456.27 +/- 182.64 microg/ml/h) about 100- to 200-fold greater than those reported for the free drug at comparable doses due to a very much lower total body clearance. Volume of distribution at steady state was 200-to 500-fold lower than for the free drug. Plasma AUC of DNRol (17.62 +/- 7.13 microg/ml x h) was similar to or even greater than that observed with free daunorubicin for comparable doses. Cumulative urinary excretion showed that about 6% and 12% of the total dose of DNX administered was excreted in urine as daunorubicin and daunorubicinol, respectively. No major toxicity was encountered. Therefore, pharmacokinetic characteristics suggest that DNX may be more convenient than free daunorubicin in the treatment of acute leukemia. In fact, liposomal formulation may allow a reduction of daunorubicin captation in normal tissues. thus minimizing toxicity at least for the parent drug, and guarantee an unimpeded access to leukemic cells in the bloodstream and bone marrow, thus theoretically improving efficacy.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s002800000163", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1088364", 
        "issn": [
          "0344-5704", 
          "1432-0843"
        ], 
        "name": "Cancer Chemotherapy and Pharmacology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "46"
      }
    ], 
    "name": "Liposomal daunorubicin plasmatic and renal disposition in patients with acute leukemia", 
    "pagination": "279-286", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "6d4042925e03397f17c9436a5069a7ded072f5cce0218e0dc885a07d59f60cdb"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "11052625"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "7806519"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s002800000163"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1022931706"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s002800000163", 
      "https://app.dimensions.ai/details/publication/pub.1022931706"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T17:26", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8672_00000488.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007/s002800000163"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s002800000163'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s002800000163'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s002800000163'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s002800000163'


 

This table displays all metadata directly associated to this object as RDF triples.

188 TRIPLES      20 PREDICATES      45 URIs      37 LITERALS      25 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s002800000163 schema:about N0a680aba935c4d1489a76bbe34bbd502
2 N11983dbb939a499a8851233b03f93621
3 N23a25eb41643409ab4fc571aeb7bc5c4
4 N261537060e19425fb50a27a569c3de48
5 N30a868f49dba4a2ead884806492e45c3
6 N4b3ae5e72976409caf477b22ef199f47
7 N5d0e950e38e84f32884002e2f2d44291
8 N657b726ea372423a837f0a2d7a04dcbf
9 N667f78991e2a4f278e3b54c4fa6ea2f8
10 N889f219867344f268f3daa2223aaaf08
11 Na71fbb8fbdfa44a9ba381cc6bbb1295e
12 Nb7149ab98d9942f0a8f37c85b7fe40fc
13 Nbb8cca2f18184fa49f89327674fce7c5
14 Nd086dde21f514088969df3d52067938d
15 Ne6e1599515f542da8f28d323bc26df8c
16 Nf051a4f059234935b1c6e7bdf895d322
17 anzsrc-for:11
18 anzsrc-for:1103
19 schema:author N586b521673d74cf88a94da94ec0e9a85
20 schema:datePublished 2000-10
21 schema:datePublishedReg 2000-10-01
22 schema:description Liposomal formulations of anthracyclines have been developed to increase their delivery to solid tumors while reducing toxicity in normal tissues. DaunoXome (DNX, NeXstar) is a liposomal-encapsulated preparation of daunorubicin registered for treatment of Kaposi's sarcoma that during prior in vitro studies showed a toxicity to leukemic cells at least comparable to that of free daunorubicin. The aim of our study was to determine DNX pharmacokinetics in 11 poor-risk patients with acute leukemia treated with DNX 60 mg/m2 IV on days 1, 3, and 5. Blood and urine samples were collected at appropriate intervals after each of the three DNX administrations. The total amount of daunorubicin (free and entrapped) (t-DNR) and of its metabolite daunorubicinol (DNRol) was assayed by HPLC. The main pharmacokinetic parameters (t1/2alpha 4.54 +/- 0.87 h; VdSS 2.88 +/- 0.93 l/m2; Cl 0.47 +/- 0.26 l/h/m2) showed that in patients with acute leukemia liposomal-entrapped daunorubicin pharmacokinetics greatly differed from that observed for the conventional formulation. In fact, DNX produced mean plasma AUC levels (t-DNR AUC0-infinity 456.27 +/- 182.64 microg/ml/h) about 100- to 200-fold greater than those reported for the free drug at comparable doses due to a very much lower total body clearance. Volume of distribution at steady state was 200-to 500-fold lower than for the free drug. Plasma AUC of DNRol (17.62 +/- 7.13 microg/ml x h) was similar to or even greater than that observed with free daunorubicin for comparable doses. Cumulative urinary excretion showed that about 6% and 12% of the total dose of DNX administered was excreted in urine as daunorubicin and daunorubicinol, respectively. No major toxicity was encountered. Therefore, pharmacokinetic characteristics suggest that DNX may be more convenient than free daunorubicin in the treatment of acute leukemia. In fact, liposomal formulation may allow a reduction of daunorubicin captation in normal tissues. thus minimizing toxicity at least for the parent drug, and guarantee an unimpeded access to leukemic cells in the bloodstream and bone marrow, thus theoretically improving efficacy.
23 schema:genre research_article
24 schema:inLanguage en
25 schema:isAccessibleForFree false
26 schema:isPartOf N611ffac1c76749bc82cdaabbfde1fc2c
27 Ne5c7819bcd704ac8ae5998a2db78f54b
28 sg:journal.1088364
29 schema:name Liposomal daunorubicin plasmatic and renal disposition in patients with acute leukemia
30 schema:pagination 279-286
31 schema:productId N154d26f5466049e5b3cbac44d5633079
32 N92e21afa4e5544fe8a09d00877fe4a92
33 Na1e03ad2877f42fa85d4f5053a99584d
34 Nf2a42c5962674a6fafe27d2858cbed2f
35 Nf7633cbef8e748078eac5621c588d34e
36 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022931706
37 https://doi.org/10.1007/s002800000163
38 schema:sdDatePublished 2019-04-10T17:26
39 schema:sdLicense https://scigraph.springernature.com/explorer/license/
40 schema:sdPublisher N7867307d785b484a8cea378cbe2f6508
41 schema:url http://link.springer.com/10.1007/s002800000163
42 sgo:license sg:explorer/license/
43 sgo:sdDataset articles
44 rdf:type schema:ScholarlyArticle
45 N0a680aba935c4d1489a76bbe34bbd502 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
46 schema:name Adult
47 rdf:type schema:DefinedTerm
48 N11983dbb939a499a8851233b03f93621 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
49 schema:name Leukemia
50 rdf:type schema:DefinedTerm
51 N154d26f5466049e5b3cbac44d5633079 schema:name readcube_id
52 schema:value 6d4042925e03397f17c9436a5069a7ded072f5cce0218e0dc885a07d59f60cdb
53 rdf:type schema:PropertyValue
54 N23a25eb41643409ab4fc571aeb7bc5c4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
55 schema:name Daunorubicin
56 rdf:type schema:DefinedTerm
57 N261537060e19425fb50a27a569c3de48 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
58 schema:name Male
59 rdf:type schema:DefinedTerm
60 N30a868f49dba4a2ead884806492e45c3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
61 schema:name Drug Carriers
62 rdf:type schema:DefinedTerm
63 N45f342ab8e634a72b48ab6e23ef22bc7 rdf:first sg:person.01016466503.33
64 rdf:rest Ndddb576bb2594376a7ee94efcf446755
65 N4b3ae5e72976409caf477b22ef199f47 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
66 schema:name Kidney
67 rdf:type schema:DefinedTerm
68 N586b521673d74cf88a94da94ec0e9a85 rdf:first sg:person.0725711337.51
69 rdf:rest Nea3ac9549f0541088daca4ca17fb1a36
70 N5d0e950e38e84f32884002e2f2d44291 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
71 schema:name Calibration
72 rdf:type schema:DefinedTerm
73 N611ffac1c76749bc82cdaabbfde1fc2c schema:volumeNumber 46
74 rdf:type schema:PublicationVolume
75 N657b726ea372423a837f0a2d7a04dcbf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
76 schema:name Female
77 rdf:type schema:DefinedTerm
78 N667f78991e2a4f278e3b54c4fa6ea2f8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
79 schema:name Liposomes
80 rdf:type schema:DefinedTerm
81 N740a0cf3715a4098b794f67bf1347100 rdf:first sg:person.0734230340.16
82 rdf:rest Ne093e491f0dc45979f750f8bdf108219
83 N7867307d785b484a8cea378cbe2f6508 schema:name Springer Nature - SN SciGraph project
84 rdf:type schema:Organization
85 N85f051702312493dadee8cb1ca28e256 rdf:first sg:person.01104271471.84
86 rdf:rest N45f342ab8e634a72b48ab6e23ef22bc7
87 N889f219867344f268f3daa2223aaaf08 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
88 schema:name Pilot Projects
89 rdf:type schema:DefinedTerm
90 N92e21afa4e5544fe8a09d00877fe4a92 schema:name dimensions_id
91 schema:value pub.1022931706
92 rdf:type schema:PropertyValue
93 N9ac2357a515342d892ae123a7d74f973 rdf:first sg:person.0633657425.75
94 rdf:rest N740a0cf3715a4098b794f67bf1347100
95 Na1e03ad2877f42fa85d4f5053a99584d schema:name pubmed_id
96 schema:value 11052625
97 rdf:type schema:PropertyValue
98 Na71fbb8fbdfa44a9ba381cc6bbb1295e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
99 schema:name Acute Disease
100 rdf:type schema:DefinedTerm
101 Nb7149ab98d9942f0a8f37c85b7fe40fc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
102 schema:name Aged
103 rdf:type schema:DefinedTerm
104 Nbb8cca2f18184fa49f89327674fce7c5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
105 schema:name Humans
106 rdf:type schema:DefinedTerm
107 Nd086dde21f514088969df3d52067938d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
108 schema:name Antibiotics, Antineoplastic
109 rdf:type schema:DefinedTerm
110 Ndddb576bb2594376a7ee94efcf446755 rdf:first sg:person.01156366337.91
111 rdf:rest rdf:nil
112 Ne093e491f0dc45979f750f8bdf108219 rdf:first sg:person.01310754205.76
113 rdf:rest N85f051702312493dadee8cb1ca28e256
114 Ne5c7819bcd704ac8ae5998a2db78f54b schema:issueNumber 4
115 rdf:type schema:PublicationIssue
116 Ne6e1599515f542da8f28d323bc26df8c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Spectrometry, Fluorescence
118 rdf:type schema:DefinedTerm
119 Nea3ac9549f0541088daca4ca17fb1a36 rdf:first sg:person.01033477037.24
120 rdf:rest N9ac2357a515342d892ae123a7d74f973
121 Nf051a4f059234935b1c6e7bdf895d322 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
122 schema:name Middle Aged
123 rdf:type schema:DefinedTerm
124 Nf2a42c5962674a6fafe27d2858cbed2f schema:name nlm_unique_id
125 schema:value 7806519
126 rdf:type schema:PropertyValue
127 Nf7633cbef8e748078eac5621c588d34e schema:name doi
128 schema:value 10.1007/s002800000163
129 rdf:type schema:PropertyValue
130 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
131 schema:name Medical and Health Sciences
132 rdf:type schema:DefinedTerm
133 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
134 schema:name Clinical Sciences
135 rdf:type schema:DefinedTerm
136 sg:journal.1088364 schema:issn 0344-5704
137 1432-0843
138 schema:name Cancer Chemotherapy and Pharmacology
139 rdf:type schema:Periodical
140 sg:person.01016466503.33 schema:affiliation https://www.grid.ac/institutes/grid.411492.b
141 schema:familyName Baccarani
142 schema:givenName Michele
143 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01016466503.33
144 rdf:type schema:Person
145 sg:person.01033477037.24 schema:affiliation https://www.grid.ac/institutes/grid.411492.b
146 schema:familyName Russo
147 schema:givenName Domenico
148 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01033477037.24
149 rdf:type schema:Person
150 sg:person.01104271471.84 schema:affiliation https://www.grid.ac/institutes/grid.411492.b
151 schema:familyName Damiani
152 schema:givenName Daniela
153 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01104271471.84
154 rdf:type schema:Person
155 sg:person.01156366337.91 schema:affiliation https://www.grid.ac/institutes/grid.5390.f
156 schema:familyName Furlanut
157 schema:givenName Mario
158 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01156366337.91
159 rdf:type schema:Person
160 sg:person.01310754205.76 schema:affiliation https://www.grid.ac/institutes/grid.411492.b
161 schema:familyName Ermacora
162 schema:givenName Anna
163 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01310754205.76
164 rdf:type schema:Person
165 sg:person.0633657425.75 schema:affiliation https://www.grid.ac/institutes/grid.418321.d
166 schema:familyName Michieli
167 schema:givenName Mariagrazia
168 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0633657425.75
169 rdf:type schema:Person
170 sg:person.0725711337.51 schema:affiliation https://www.grid.ac/institutes/grid.5390.f
171 schema:familyName Pea
172 schema:givenName Federico
173 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0725711337.51
174 rdf:type schema:Person
175 sg:person.0734230340.16 schema:affiliation https://www.grid.ac/institutes/grid.5390.f
176 schema:familyName Baraldo
177 schema:givenName Massimo
178 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0734230340.16
179 rdf:type schema:Person
180 https://www.grid.ac/institutes/grid.411492.b schema:alternateName Ospedale Santa Maria della Misericordia di Udine
181 schema:name Department of Medical and Morphologic Research and Division of Hematology, Udine University Hospital, P.le S.M. Misericordia, 3, 33100 Udine, Italy, IT
182 rdf:type schema:Organization
183 https://www.grid.ac/institutes/grid.418321.d schema:alternateName Centro di Riferimento Oncologico
184 schema:name Division of Medical Oncology, CRO, Istituto Nationale Tumori, Aviano, Italy, IT
185 rdf:type schema:Organization
186 https://www.grid.ac/institutes/grid.5390.f schema:alternateName University of Udine
187 schema:name Institute of Clinical Pharmacology and Toxicology, Chair of Pharmacology, DPMSC, University of Udine, P.le S.M. Misericordia, 3, 33100 Udine, Italy e-mail: federico.pea@med.uniud.it Tel.: +39-0432-559833; Fax: +39-0432-559833, IT
188 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...